Temporally restricted activation of IFNβ signaling determines response to immune checkpoint therapy

Citation:
Zemek R, Chin WL, Fear V, Wylie B, Casey T, Forbes C, ….... Bosco A, Forrest a, Millward M, ……… Lassmann T, Lesterhuis J. Temporally restricted activation of IFNβ signaling determines response to immune checkpoint therapy. Nature Communications. 2022 13(1).

Keywords:
Immune checkpoints; PD-1; CTLA4; type I interferon; IFNβ; gene regulatory networks; time-dependent; RNAseq; biomarker; drug discovery

Abstract:
The biological determinants of the response to immune checkpoint blockade (ICB) in cancer remain incompletely understood. Little is known about dynamic biological events that underpin therapeutic efficacy due to the inability to frequently sample tumours in patients.